Octagon Capital Advisors LP / KROS
Octagon Capital Advisors LP’s Keros Therapeutics Inc Position
Does Octagon Capital Advisors LP own Keros Therapeutics Inc (KROS)? Not currently — the last reported position was 152.2K shares worth $4M in Q2 2022; the fund’s latest 13F (Q1 2026) no longer reports it.
Position Value
$4M
Q2 2022
Shares
152.2K
% of Portfolio
+1.12%
Quarters Held
3
position exited
Position History KROS
Reported value by quarter
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Octagon Capital Advisors LP’s full portfolio or all institutional holders of KROS.